Up to a fifth of patients with colorectal cancer (CRC) present with synchronous hepatic
metastases. In patients with CRC who present without intestinal obstruction or perforation …

Colorectal cancer (CRC) is a major contributor to cancer-associated morbidity worldwide
and over one-third of CRC is located in the rectum. Neoadjuvant chemoradiotherapy (nCRT) …

Background Clinical trials have recently evaluated safety and efficacy of neoadjuvant
therapy among patients with surgically resectable regional melanoma metastases. To …

Aim Pathological complete response to neoadjuvant chemoradiotherapy is found in 20% of
patients with rectal cancer undergoing long‐course chemoradiotherapy. Some authors have …

Tumour hypoxia contributes to poor treatment outcome in locally advanced rectal cancer
(LARC) and circulating extracellular vesicles (EVs) as potential biomarkers of tumour …

Purpose Pathologic complete response (pCR) to neoadjuvant treatment for rectal cancer
has been associated with improved local control, reduced distant disease and a survival …

Objective High rates of systemic failure in locally advanced rectal cancer call for a rational
use of conventional therapies to foster tumor-defeating immunity. Methods We analyzed the …

Chemo-/radiotherapy resistance is the main cause accounting for most treatment failure in
colorectal cancer (CRC). Tumor-initiating cells (TICs) are the culprit leading to CRC chemo …

Despite the continuous advancement of surgical resection techniques, postoperative tumor
recurrence and metastasis remain a huge challenge. Here, we constructed an injectable …

Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the mainstay treatment for
locally advanced rectal cancer. Variable degrees of tumor regression are observed after …